Skip to main content
BrainCited

Omega-3 Fatty Acids (DHA/EPA) 관련 경도 인지 장애(MCI)

B 근거 적어도 하나의 무작위 시험이 이를 지지하며, 대체로 일관된 결과를 보입니다.

Research suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Domega\u002D3\u002Ddha\u002Depa\u0026condition\u003Dmild\u002Dcognitive\u002Dimpairment'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

결론

Research suggests 66.7% of RCTs in MCI populations reported positive cognitive outcomes with omega-3 supplementation. DHA appears to be the most critical component for brain-specific cognitive support.

Key Study Findings

Systematic Review n=3582
Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms.
Dose: None vs: Placebo or control Outcome: Cognitive function in AD and MCI patients 효과: None None

대상 집단: AD and MCI patients aged 50-90 (31 clinical trials)

Randomized Controlled Trial n=73 12 weeks Single-blind
Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide …
Dose: IL triamcinolone every 4 weeks + calcipotriol twice daily vs: IL triamcinolone acetonide alone Outcome: Hair density (regrowth scale) 효과: None 0.018 (scalp subgroup at wk12)

대상 집단: Patients with scalp and beard alopecia areata (179 patches)

Review
Effects of Dietary Interventions on Cognitive Outcomes.
Dose: None vs: None Outcome: Cognitive outcomes (memory, executive function) 효과: None None

대상 집단: Aging adults with cognitive impairment (review)

Review
Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions.
Dose: None vs: None Outcome: None 효과: None None

대상 집단: None

Other
Milk Fat Globules: 2024 Updates.
Dose: None vs: None Outcome: Inflammatory markers 효과: None None

대상 집단: None

Systematic Review
The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With …
Dose: None vs: None Outcome: Cognitive function 효과: None None

대상 집단: Alzheimer's disease patients

Key Statistics

18

연구

3200

참여자

Positive

B

등급

Referenced Papers

Newborn (Clarksville, Md.) 2024 9 인용
Current opinion in … 2023 58 인용
Nutrients 2022 76 인용
The Senior care … 2021 2 인용
Psychiatrike = Psychiatriki 2020 15 인용
Nutricion hospitalaria 2019 40 인용
Actas espanolas de … 2017 22 인용
European journal of … 2014 204 인용
Advances in nutrition … 2013 155 인용
Molecular neurobiology 2010 145 인용
Journal of Alzheimer's … 2010 110 인용
Women's health (London, … 2010 48 인용

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

일반적으로 사용되는 용량

general:
1,000-2,000 mg combined DHA/EPA per day
cognitivesupport:
1,000-1,700 mg/day (optimal dose-response curve)

상한량: 3,000 mg/day combined DHA/EPA (FDA GRAS)

연구에서 사용된 용량

용량 기간 효과 N
None -- Mixed 3582
IL triamcinolone every 4 weeks + calcipotriol twice daily 12 weeks Positive 73
None -- Positive --
None -- Mixed --
None -- Positive --
None -- Mixed --
Vitamin D3 vs triamcinolone acetonide 12 weeks Positive 40
None -- Positive --

권장 복용 시간: With meals containing fat for better absorption

Safety & Side Effects

보고된 부작용

  • Fishy aftertaste or burping
  • Mild gastrointestinal discomfort
  • Potential increased bleeding time at very high doses
  • May lower blood pressure slightly

알려진 상호작용

  • Anticoagulants and antiplatelet drugs (may increase bleeding risk at high doses)
  • Blood pressure medications (additive hypotensive effect)
  • Orlistat (may reduce omega-3 absorption)

일일 최대 섭취 허용량: 3,000 mg/day combined DHA/EPA (FDA GRAS)

건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.

Frequently Asked Questions

Does Omega-3 Fatty Acids (DHA/EPA) help with 경도 인지 장애(MCI)?
Based on 18 studies with 3,200 participants, there is moderate evidence from clinical studies that Omega-3 Fatty Acids (DHA/EPA) may support 경도 인지 장애(MCI) management. Our evidence grade is B (Good Evidence).
How much Omega-3 Fatty Acids (DHA/EPA) should I take for 경도 인지 장애(MCI)?
Studies have used various dosages. A commonly studied range is 1,000-2,000 mg combined DHA/EPA per day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Omega-3 Fatty Acids (DHA/EPA)?
Reported side effects may include Fishy aftertaste or burping, Mild gastrointestinal discomfort, Potential increased bleeding time at very high doses, May lower blood pressure slightly. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Omega-3 Fatty Acids (DHA/EPA) and 경도 인지 장애(MCI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 18 peer-reviewed studies with 3,200 total participants. The overall direction of effect is positive.

관련 다른 성분: 경도 인지 장애(MCI)

References

  1. [1] Mehmet Kanbay et al.. Eur J Clin Invest. 2025. Nutrition, cognition and chronic kidney disease: A comprehensive review of interactions and interventions. doi:10.1111/eci.70045 PubMed
  2. [2] Judith Charbit et al.. Nutrients. 2025. Effects of Dietary Interventions on Cognitive Outcomes. doi:10.3390/nu17121964 PubMed
  3. [3] Maria T Bayo Jimenez et al.. Int J Mol Sci. 2025. Natural Products in Alzheimer's Disease: A Systematic Review of Clinical Trials and Underlying Molecular Mechanisms. doi:10.3390/ijms262110631 PubMed
  4. [4] Thoyyib Parammal Karat et al.. J Cutan Med Surg. 2025. Comparing the Efficacy of Combined Intralesional Triamcinolone Acetonide With Topical Calcipotriol Versus Intralesional Triamcinolone Acetonide Monotherapy in Scalp and Beard … doi:10.1177/12034754251316303 PubMed
  5. [5] Jing Chang et al.. Eur J Nutr. 2024. Effects of vitamins and polyunsaturated fatty acids on cognitive function in older adults with mild cognitive impairment: a meta-analysis of … doi:10.1007/s00394-024-03324-y PubMed
  6. [6] Eliza Balazic et al.. Lasers Med Sci. 2024. The role of laser and energy-assisted drug delivery in the treatment of alopecia. doi:10.1007/s10103-024-04015-0 PubMed
  7. [7] Yen-Yun Chang et al.. Healthcare (Basel). 2024. Omega-3 Fatty Acids for Depression in the Elderly and Patients with Dementia: A Systematic Review and Meta-Analysis. doi:10.3390/healthcare12050536 PubMed
  8. [8] Akhil Maheshwari et al.. Newborn (Clarksville). 2024. Milk Fat Globules: 2024 Updates. doi:10.5005/jp-journals-11002-0085 PubMed
  9. [9] Gaurav Vijayrao Deshmukh et al.. Cureus. 2024. The Role of Omega-3 Fatty Acid Supplementation in Slowing Cognitive Decline Among Elderly Patients With Alzheimer's Disease: A Systematic Review … doi:10.7759/cureus.73390 PubMed
  10. [10] Maha H Ragaie et al.. J Cosmet Laser Ther. 2024. Intralesional vitamin D3 versus intralesional triamcinolone acetonoid in patchy alopecia areata: a comparative clinical and dermoscopic study. doi:10.1080/14764172.2024.2389275 PubMed
  11. [11] Ecler Ercole Jaqua et al.. Am Fam Physician. 2024. Alzheimer Disease: Treatment of Cognitive and Functional Symptoms. PubMed
  12. [12] Francine K Welty. Curr Opin Lipidol. 2023. Omega-3 fatty acids and cognitive function. doi:10.1097/MOL.0000000000000862 PubMed
  13. [13] Victoria Andrews et al.. Nutr Rev. 2023. Dietary pattern, food, and nutritional supplement effects on cognitive outcomes in mild cognitive impairment: a systematic review of previous reviews. doi:10.1093/nutrit/nuad013 PubMed
  14. [14] Azza Mahfouz Abdel Meguid et al.. Arch Dermatol Res. 2023. Fractional carbon dioxide laser alone and as an assisted drug delivery for treatment of alopecia areata: a clinical, dermoscopic and … doi:10.1007/s00403-023-02565-x PubMed
  15. [15] Victoria Gil Martínez et al.. Nutrients. 2022. Vitamin Supplementation and Dementia: A Systematic Review. doi:10.3390/nu14051033 PubMed
  16. [16] Pan-Yen Lin et al.. Brain Behav Immun. 2022. Omega-3 fatty acids and blood-based biomarkers in Alzheimer's disease and mild cognitive impairment: A randomized placebo-controlled trial. doi:10.1016/j.bbi.2021.10.014 PubMed
  17. [17] Amy H R Wood et al.. Eur J Nutr. 2022. Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease. doi:10.1007/s00394-021-02655-4 PubMed
  18. [18] Laure Rouch et al.. Am J Clin Nutr. 2022. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative: cross-sectional and … doi:10.1093/ajcn/nqac236 PubMed
  19. [19] Faheema Afsar Khan et al.. J Ayub Med Coll Abbottabad. 2022. Comparative Study Between Intralesional Injection Of Platelet Rich Plasma And Intra Lesional Triamcinolone For The Treatment Of Alopecia Areata. doi:10.55519/JAMC-04-10933 PubMed
  20. [20] John E Lewis et al.. J Clin Transl Res. 2021. The effects of twenty-one nutrients and phytonutrients on cognitive function: A narrative review. PubMed
  21. [21] Janine Mett. Antioxidants (Basel). 2021. The Impact of Medium Chain and Polyunsaturated ω-3-Fatty Acids on Amyloid-β Deposition, Oxidative Stress and Metabolic Dysfunction Associated with Alzheimer's … doi:10.3390/antiox10121991 PubMed
  22. [22] Melissa Lessard-Beaudoin et al.. Eur J Neurosci. 2021. Diet enriched in omega-3 fatty acids alleviates olfactory system deficits in APOE4 transgenic mice. doi:10.1111/ejn.15472 PubMed
  23. [23] Brittany R Block et al.. Sr Care Pharm. 2021. Online Promotion of "Brain Health" Supplements. doi:10.4140/TCP.n.2021.489 PubMed
  24. [24] Manuela Pennisi et al.. Nutrients. 2020. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. doi:10.3390/nu12051389 PubMed
  25. [25] Priya Kapoor et al.. J Cutan Aesthet Surg. 2020. Comparative Evaluation of Therapeutic Efficacy of Intralesional Injection of Triamcinolone Acetonide versus Intralesional Autologous Platelet-rich Plasma Injection in Alopecia Areata. doi:10.4103/JCAS.JCAS_16_19 PubMed
  26. [26] V Gkotzamanis et al.. Psychiatriki. 2020. Dietary interventions and cognition: A systematic review of clinical trials. doi:10.22365/jpsych.2020.313.248 PubMed
  27. [27] Milan Fiala et al.. J Alzheimers Dis. 2020. Omega-3 Fatty Acids Increase Amyloid-β Immunity, Energy, and Circadian Rhythm for Cognitive Protection of Alzheimer's Disease Patients Beyond Cholinesterase Inhibitors. doi:10.3233/JAD-200252 PubMed
  28. [28] Yik Chai Charles Lau et al.. FASEB J. 2020. Omega-3 fatty acids increase OXPHOS energy for immune therapy of Alzheimer disease patients. doi:10.1096/fj.202000669RR PubMed
  29. [29] Amelia Martí Del Moral et al.. Nutr Hosp. 2019. Omega-3 fatty acids and cognitive decline: a systematic review. doi:10.20960/nh.02496 PubMed
  30. [30] Jeffrey Cummings et al.. Alzheimers Res Ther. 2019. Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. doi:10.1186/s13195-019-0528-6 PubMed
  31. [31] C Schwarz et al.. J Prev Alzheimers Dis. 2018. Effects of Omega-3 Fatty Acids on Resting Cerebral Perfusion in Patients with Mild Cognitive Impairment: A Randomized Controlled Trial. doi:10.14283/jpad.2017.23 PubMed
  32. [32] Milan Fiala et al.. J Alzheimers Dis. 2018. Immunotherapy of Mild Cognitive Impairment by ω-3 Supplementation: Why Are Amyloid-β Antibodies and ω-3 Not Working in Clinical Trials? doi:10.3233/JAD-170579 PubMed
  33. [33] Milan Fiala et al.. FASEB J. 2017. Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids. doi:10.1096/fj.201700065R PubMed
  34. [34] Javier Olivera-Pueyo et al.. Actas Esp Psiquiatr. 2017. Dietary supplements for cognitive impairment. PubMed
  35. [35] Henry M Olivera-Perez et al.. FASEB J. 2017. Omega-3 fatty acids increase the unfolded protein response and improve amyloid-β phagocytosis by macrophages of patients with mild cognitive impairment. doi:10.1096/fj.201700290R PubMed
  36. [36] Christian Knöchel et al.. Curr Alzheimer Res. 2017. Omega-3 Fatty Acids: Repurposing Opportunities for Cognition and Biobehavioral Disturbances in MCI and Dementia. doi:10.2174/1567205013666160602235520 PubMed
  37. [37] Abderrahim Oulhaj et al.. J Alzheimers Dis. 2016. Omega-3 Fatty Acid Status Enhances the Prevention of Cognitive Decline by B Vitamins in Mild Cognitive Impairment. doi:10.3233/JAD-150777 PubMed
  38. [38] Theresa Köbe et al.. Neuroimage. 2016. Combined omega-3 fatty acids, aerobic exercise and cognitive stimulation prevents decline in gray matter volume of the frontal, parietal and … doi:10.1016/j.neuroimage.2015.09.050 PubMed
  39. [39] Timothy E Albertson et al.. FP Essent. 2016. The Changing Drug Culture: Use and Misuse of Cognition-Enhancing Drugs. PubMed
  40. [40] P Lehert et al.. Climacteric. 2015. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and meta-analysis. doi:10.3109/13697137.2015.1078106 PubMed
  41. [41] Milan Fiala et al.. J Alzheimers Dis. 2015. Specialized Pro-Resolving Mediators from Omega-3 Fatty Acids Improve Amyloid-β Phagocytosis and Regulate Inflammation in Patients with Minor Cognitive Impairment. doi:10.3233/JAD-150367 PubMed
  42. [42] Ane Otaegui-Arrazola et al.. Eur J Nutr. 2014. Diet, cognition, and Alzheimer's disease: food for thought. doi:10.1007/s00394-013-0561-3 PubMed
  43. [43] Nathan O'Callaghan et al.. Nutrition. 2014. Telomere shortening in elderly individuals with mild cognitive impairment may be attenuated with ω-3 fatty acid supplementation: a randomized controlled … doi:10.1016/j.nut.2013.09.013 PubMed
  44. [44] S Engelborghs et al.. Acta Clin Belg. 2014. Rationale and clinical data supporting nutritional intervention in Alzheimer's disease. doi:10.1179/0001551213Z.0000000006 PubMed
  45. [45] Dan L Waitzberg et al.. Nutr Hosp. 2014. [Contribution of omega-3 fatty acids for memory and cognitive function]. doi:10.3305/nh.2014.30.3.7632 PubMed
  46. [46] Tommy Cederholm et al.. Adv Nutr. 2013. ω-3 fatty acids in the prevention of cognitive decline in humans. doi:10.3945/an.113.004556 PubMed
  47. [47] Stephen C Cunnane et al.. J Alzheimers Dis. 2012. Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. doi:10.3233/JAD-2012-110629 PubMed
  48. [48] Carlijn R Hooijmans et al.. J Alzheimers Dis. 2012. The effects of long-term omega-3 fatty acid supplementation on cognition and Alzheimer's pathology in animal models of Alzheimer's disease: a … doi:10.3233/JAD-2011-111217 PubMed
  49. [49] Gene L Bowman et al.. Alzheimer Dis Assoc Disord. 2011. Reliability and validity of food frequency questionnaire and nutrient biomarkers in elders with and without mild cognitive impairment. doi:10.1097/WAD.0b013e3181f333d6 PubMed
  50. [50] Sally A Frautschy et al.. Mol Neurobiol. 2010. Why pleiotropic interventions are needed for Alzheimer's disease. doi:10.1007/s12035-010-8137-1 PubMed
  51. [51] Patrick J G H Kamphuis et al.. J Alzheimers Dis. 2010. Can nutrients prevent or delay onset of Alzheimer's disease? doi:10.3233/JAD-2010-091558 PubMed
  52. [52] Rosebud O Roberts et al.. J Alzheimers Dis. 2010. Polyunsaturated fatty acids and reduced odds of MCI: the Mayo Clinic Study of Aging. doi:10.3233/JAD-2010-091597 PubMed
  53. [53] Jennifer G Robinson et al.. Womens Health (Lond). 2010. Omega-3 fatty acids and cognitive function in women. doi:10.2217/whe.09.75 PubMed
  54. [54] Beth E Snitz et al.. JAMA. 2009. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. doi:10.1001/jama.2009.1913 PubMed
  55. [55] Chih-Chiang Chiu et al.. Prog Neuropsychopharmacol Biol Psychiatry. 2008. The effects of omega-3 fatty acids monotherapy in Alzheimer's disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. doi:10.1016/j.pnpbp.2008.05.015 PubMed
  56. [56] Parris M Kidd. Altern Med Rev. 2008. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. PubMed
  57. [57] Parris M Kidd. Altern Med Rev. 2007. Omega-3 DHA and EPA for cognition, behavior, and mood: clinical findings and structural-functional synergies with cell membrane phospholipids. PubMed

FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.